In Brief
Liu et al. demonstrate the emergence of redundant adaptive NK cell subsets in NKG2C À/À donors. Functional studies unraveled a critical role for CD2 in antibody-dependent responses by adaptive NK cells, paving the way for new strategies to harness their cytotoxic potential in cell therapy.
INTRODUCTION
Human cytomegalovirus (HCMV) is a persistent betaherpes virus with a worldwide prevalence ranging between 50% and 100% of the population depending on socioeconomic factors. Congenital HCMV infection is a leading cause of sensorineural hearing loss in children and a significant cause of neurodevelopmental delay (Manicklal et al., 2013) . Immunocompromised patients with AIDS, severe combined immunodeficiency (SCID), or those having received immunosuppressive treatment in conjunction with hematopoietic stem cell transplantation (HSCT), frequently experience life-threatening HCMV infection. Adaptive immunity plays a crucial role in the control of HCMV (Crough and Khanna, 2009 ). HCMV-specific T cells have a terminally differentiated phenotype and can represent up to 40% of the total T cell memory pool (Sylwester et al., 2005; van Lier et al., 2003) . Natural killer (NK) cells are innate lymphocytes involved in numerous physiological processes including reproduction (Parham and Moffett, 2013) and immunity to infections (Jost and Altfeld, 2013) . Recent advances in NK cell biology suggest that NK cells display adaptive features during CMV infection, contributing to viral control (Vivier et al., 2011) . Unlike T and B cell immune responses, CMV-driven adaptive NK cell responses do not rely on receptor rearrangement. In mice, infection with mouse CMV (MCMV) leads to a clonal expansion of NK cells expressing the activating receptor Ly49H, which binds to the MCMV-encoded protein m157 (Arase et al., 2002) . Optimal differentiation of adaptive Ly49H + NK cells depends on delivery of ''signal 2,'' provided through co-stimulation via DNAM-1 (Nabekura et al., 2014) . The expansion and contraction within the Ly49H + NK cell population result in a pool of memory NK cells that mediate long-lasting protection against subsequent challenges with the virus (Sun et al., 2009) . In humans, the NK cell response against HCMV results in a stable imprint of highly differentiated NK cells expressing DAP12-coupled receptors including NKG2C and activating killer cell immunoglobulin-like receptors (KIRs) (Bé ziat et al., 2013; Gumá et al., 2004) . Expansion of these NK cell subsets, referred to as adaptive NK cells, have been observed following HCMV reactivation in transplanted patients (Della Chiesa et al., 2014; Foley et al., 2012; Lopez-Vergè s et al., 2011) and was associated with viral control in a T -B + NK + SCID patient experiencing acute primary HCMV infection (Kuijpers et al., 2008) .
Despite accumulating evidence that NKG2C plays a central role in the NK cell response against HCMV, NKG2C is dispensable for survival and reproduction. Approximately 20% of human haplotypes carry a full deletion of the KLRC2/NKG2C gene (hereafter referred to as NKG2C only) (Miyashita et al., 2004; Moraru et al., 2012b; Thomas et al., 2012) . Accordingly, approximately 4% of the human population completely lacks the NKG2C gene (NKG2C
À/À
). Although lack of NKG2C has been linked to an increased risk of HIV progression (Thomas et al., 2012) , it is not overrepresented in children with severe congenital HCMV infection (Noyola et al., 2012) , and HCMV seropositive NKG2C À/À adults remain healthy without specific symptoms. The lack of a clinical phenotype raises the question of whether adaptive NK cell responses are physiologically relevant or if other cellular mechanisms compensate for the loss of NKG2C-driven adaptive NK cell responses. Here, comparative studies of HCMV immunity in large cohorts of NKG2C-sufficient and -deficient individuals revealed an unexpected redundancy in the adaptive NK cell response and point to a critical role for CD2 in providing co-stimulation for NKG2C-and antibody-mediated triggering of adaptive NK cells.
RESULTS

Minimal Imprint in T Cell Immunity in Individuals Carrying Homozygous Deletion of NKG2C
The absence of more severe HCMV infection in NKG2C (Miyashita et al., 2004; Moraru et al., 2012b; Thomas et al., 2012) . We then prospectively obtained buffy coats from 60 of these for downstream analyses. The demographics of the NKG2C À/À cohort and of the agematched NKG2C + controls (NKG2C +/À and NKG2C +/+ ) are summarized in Table S1 . We analyzed the impact of homozygous NKG2C deletion on the differentiation profile and the anti-HCMV response of CD4 and CD8 T cells from NKG2C À/À donors as compared to S1 , and S2). We found that the NKG2C deletion resulted in a slight but statistically significant accumulation of terminally differentiated effector memory CD45RA + (CCR7 -CD45RA + ) cells in the CD8 + T cell compartment (24.1 ± 14.4 versus 32.3 ± 16.9, p = 0.014), whereas no significant changes were observed for any of the other CD8 T cell subsets studied (Figures S1A and S1B). Interestingly, the accumulation of mature CD8 T cells was particularly visible in young and middle-age individuals (17.8 ± 9.6 versus 32.07 ± 17.2, p = 0.001; Figures 1A-1C) . However, CD8 T cell responses following stimulation with overlapping peptide pools derived from the HCMV proteins IE-1, IE-2, and pp65 were identical in NKG2C À/À and NKG2C + individuals, regardless of age ( Figures 1D, S1C , and S1D). These results were confirmed by using HLA-A*02 and HLA-B*07 tetramers refolded with pp65-derived immunodominant peptides to detect HCMV-specific CD8 T cells ( Figures 1E, S1E , and S1F). Similarly, NKG2C deletion was not associated with any significant phenotypic or functional differences in CD4 + T cells (Figure S2) and did not imprint B cell differentiation ( Figure S3 (Bé ziat et al., 2013 (Bé ziat et al., , 2014 Zhang et al., 2013) . To examine the possible existence of adaptive NK cells in NKG2C À/À donors, we analyzed multiparametric flow cytometry data by non-linear dimensionality reduction using t-distributed stochastic neighbor embedding (t-SNE) ( Figure 2A ) (Amir et al., 2013 3C ). More importantly, they shared functional attributes of adaptive NK cells observed in NKG2C + individuals. First, they had a poor ability to produce interferon (IFN)-g after interleukin-12 (IL-12)/IL-18 stimulation ( Figure 3D ). Second, they displayed decreased degranulation capacity, measured via cell-surface expression of CD107a, upon direct interaction with K562 (p = 0.0046) and RAJI (p = 0.0005) cells and displayed enhanced IFN-g (p < 0.0001) and tumor necrosis factor (TNF) (p = 0.0002) production against antibody-coated target cells compared to conventional NK cells ( Figures 3E-3G ). Third, in line with the enhanced ability to produce IFN-g, compared to conventional NK cells, they displayed a clear epigenetic remodeling associated with demethylation of CpG motifs in the conserved noncoding sequence (CNS) 1 of the IFNG locus (Figure 3H Previous reports suggest that activating KIRs may compensate for the loss of NKG2C in donors with a homozygous NKG2C deletion (Bé ziat et al., 2013; Della Chiesa et al., 2014) . Accordingly, we examined the relative contribution of NKG2C and activating KIRs to the adaptive NK cell pool in each donor ( Figure 4E ). In NKG2C + donors, 60% of the expansions expressed only NKG2C, 27% co-expressed NKG2C and an activating KIR (KIR2DS1, KIR2DS2, KIR3DS1, or KIR2DS4), whereas 13% of the expansions expressed predominantly an activating KIR. Surprisingly, we found similar overall frequencies of activating KIR-positive expansions in NKG2C À/À individuals (36%) ( Figure 4E ). Moreover, the magnitude of the adaptive response, determined as the fraction of adaptive NK cells within the total NK cell subset, did not differ in donors with and without the NKG2C deletion and seemed to be independent of the activating receptor composition ( Figure 4F ). Although our phenotypic analysis did not include KIR2DS3 and KIR2DS5, the detection of three haplotype A/A donors among the 11 NKG2C À/À donors with an expansion allowed us to conclude that the expression of NKG2C and/or activating KIRs are not prerequisites for the emergence of adaptive NK cells.
CD2 and CD16 Synergistically Activate Adaptive NK Cells
The finding that adaptive NK cell responses can occur independently of NKG2C and activating KIRs prompted us to revisit the potential role of other activating receptors expressed by NK cells. We found a profound downregulation of NKp46, stable expression or weak downregulation of 2B4, NTB-A, CRACC, and NKG2D and an increased expression of DNAM-1 and CD2 in adaptive NK cells of both NKG2C À/À and NKG2C + donors (Figures 5A, 5B, and S5A). Next, we addressed whether any particular activating receptors could co-stimulate human adaptive NK cells in a fashion similar to that described for DNAM-1 in Ly49H-driven responses in the mouse (Nabekura et al., 2014) . Since it was recently shown that antibody-mediated recognition of CMV-infected cells can drive the expansion of adaptive NK cells , we tested the ability of CD2 ( Figures 5C and S5B ), 2B4, and DNAM-1 ( Figure S5C ) to co-stimulate the CD16 pathway in adaptive NK cells from both NKG2C À/À and NKG2C + donors. Agonistic stimulation of CD2
and CD16 using antibody-coated P815 cells revealed a striking synergistic interaction between CD2 and CD16 that was not observed for any other receptor combinations or in conventional NK cells. Thus, ligation of CD16 together with CD2 led to an increase in IFN-g and TNF-producing cells compared to CD16 stimulation alone ( Figures 5C and S5B ). Titrating the dose of CD16 revealed that CD2 engagement enhanced the maximum response compared to CD16 crosslinking alone without influencing the response threshold ( Figure 5D ). Next, we explored the potential contribution of CD2 to antibody-triggered responses by adaptive and conventional NK cells. To this end, we made use of the CD20 + RAJI B cell lymphoma line, which expresses CD58, the ligand of CD2. We monitored functional responses in the two subsets following incubation with anti-CD20 (rituximab)-coated RAJI cells. CD2 blockade led to a profound decrease of IFN-g and TNF production as well as degranulation ( Figure 5E ). The costimulatory effect of CD2 was evident at low rituximab concentrations, suggesting that this pathway may boost the CD16 responses in the context of low levels of immunoglobulins. The blocking of CD2 also revealed a modest but significant synergy between CD2 and CD16 in conventional NK cells for IFN-g and TNF production ( Figure 5E Figure 5F ). Blockade of CD2 interactions with its natural ligand in target cell assays with HLA-E-expressing 221 cells had a broader effect and diminished the response in both conventional and adaptive NK cells ( Figure 5G ), potentially attributed to an additional effect on target cell adhesion (Hahn and Bierer, 1993) . Together these results reveal a unique role for CD2 in specifically boosting functional responses mediated through CD16 and NKG2C in adaptive NK cells.
CD2 Co-stimulation Boosts the CD16 Signaling Cascade
To dissect the mechanism underlying CD2 costimulation in adaptive NK cells, we monitored the phosphorylation kinetics of key signaling molecules downstream of CD16, including CD3-z, ZAP70/Syk, SLP76, LAT, ERK1/2 (MAP kinase pathway), and S6RP (mTORC pathway), using phosphoflow cytometry ( Figures 6A-6D ) (Long et al., 2013) . Unlike T cells (Kaizuka et al., 2009) , no signaling events was induced in conventional or adaptive NK cells when triggered with anti-CD2 alone ( Figures  6B-6D ). In contrast, CD16 crosslinking induced phosphorylation of all signaling molecules tested in both NK subsets. In line with the functional readouts, CD16-induced phosphorylation of SLP76, ERK1/2, and S6RP was stronger in adaptive compared to conventional NK cells ( Figure 6D ). In conventional NK cells, we noted a weak synergy between CD2 and CD16 that was significant for the phosphorylation of ERK1/2 after 1 min (mean ratio 1.6 versus 1.9, p = 0.0006) and S6RP after 10 min (mean ratio 6.6 versus 10.3, p < 0.0001). In adaptive NK cells, however, co-ligation of CD2 and CD16 led to significantly higher levels of (legend continued on next page) phosphorylation of all signaling molecules. This synergistic induction of signaling in adaptive NK cells was particularly pronounced for ERK1/2 after 5 min (mean ratio 2.9 versus 3.9, p = 0.017) and S6RP after 10 min (mean ratio 25.5 versus 39.8, p = 0.0066). Taken together, these results demonstrate that the costimulation of CD16 by CD2 is mechanistically linked to the synergistic induction of the MAP kinase and mTORC pathways.
DISCUSSION
During the last decade, it has become clear that NK cells possess the ability to calibrate their functional potential and respond to pathogenic challenges in a fashion that is commonly attributable to cells within the adaptive immune system. However, the natural drivers behind these responses remain largely unknown. In the mouse, the activating receptor Ly49H has probably evolved to counteract the decoy major histocompatibility complex (MHC) class I molecule in MCMV, m157, which allows the virus to escape NK cells expressing the inhibitory receptor Ly49C (Forbes et al., 2014; Pyzik et al., 2014) . However, Ly49H is not found in all mouse strains suggesting that it is not required for survival in natura, despite the protection it confers against MCMV in certain laboratory strains (Arase et al., 2002 Orbelyan et al., showing that NKG2E is retained within the endoplasmic reticulum due to hydrophobic amino acids in the extracellular domain of the protein (Orbelyan et al., 2014) . A broad profiling of activating receptor expression on adaptive NK cells from NKG2C À/À donors, we noted increased levels of DNAM-1 and CD2, two receptors that synergize with NKp46 to trigger resting NK cells (Bryceson et al., 2006) . DNAM-1 expression is enhanced in educated NK cells and cooperates with LFA-1 to form stable target cell conjugates (Enqvist et al., 2015) . In mice, DNAM-1 marks NK cell maturation (Martinet et al., 2015) and was found to be critical for the expansion of Ly49H + NK cells after MCMV infection (Nabekura et al., 2014) .
Although our results do not exclude the involvement of DMAM-1 in the early phase of adaptive NK cell expansion and differentiation in the human, we did not observe costimulatory potential of this receptor in adaptive NK cells. Therefore, we turned our attention to CD2. CD2 is a major coactivating receptor expressed on NK and T cell subsets (Davis and van der Merwe, 1996) ; it recognizes CD58, a ligand expressed on a wide variety of tissues (Smith and Thomas, 1990) . In resting conventional NK cells, cross-linking of CD2 with NKp46 increases the intracellular calcium flux, but not cytokine production or degranulation (Bryceson et al., 2006) . Extending these results, we here describe a potent synergy between CD2 and CD16 that is unique to adaptive NK cells. Furthermore, CD2 ligation co-stimulated NKG2C-mediated responses in adaptive NK cells from NKG2C + donors, suggesting that CD2 plays a broad role in the functionality of adaptive NK cells.
Notably, patients with homozygous missense mutations in CD16 have poor natural cytotoxicity, which is attributable to the loss of physical interactions between CD16 and CD2 (Grier et al., 2012) . CD16 stabilizes the expression of CD2 and the two molecules co-localize at the immune synapse allowing CD2 to tap into the signaling pathway downstream of CD16. CD16 and NKG2C are associated with dimers of immunoreceptor tyrosine-based activation motif (ITAM)-containing molecules, FcεR1g and/or CD3-z for CD16 and DAP12 for NKG2C (Lanier, 2008) . CD3-z and DAP12 are expressed in all NK cells, while FcεR1g is often downregulated in adaptive NK cells Schlums et al., 2015; Zhang et al., 2013) . As a consequence, in adaptive NK cells, CD16 is mostly associated with CD3-z/CD3-z homodimers (eight ITAMs) instead of CD3-z/ FcεR1g (six ITAMs) or FcεR1g/FcεR1g (four ITAMs) dimers. Since CD2 signaling was shown to be dependent on CD3-z (Moingeon et al., 1992; Vivier et al., 1991) , it is tempting to speculate that this quantitative difference in ITAM motif contributes to the enhanced CD16 responses in adaptive NK cells. Supporting this notion, our data show that CD2 co-activation of CD16 in adaptive FcεR1g -NK cells leads to an increase phosphorylation of CD3-z as well as of all the other signaling molecules we tested. However, only a fraction of adaptive NK cells are FcεR1g - (Schlums et al., 2015) , and NKG2C + FcεR1g + adaptive NK cells also exhibited heightened responses to CD2 and CD16 costimulation (data not shown), suggesting that alternative signaling pathways may be involved.
Adaptive NK cells displayed enhanced phosphorylation of ERK and S6RP upon CD16 and CD2 co-activation. ERK is a major hub of signal transduction in the MAP-kinase pathway, whereas S6RP is downstream of the mTORC1 complex; both are late signaling events involved in numerous central processes in lymphocytes, including proliferation, differentiation, and cytokine production (Dong et al., 2002; Pollizzi and Powell, 2014) .
Recently, mTORC pathway activity was shown to be essential for mouse NK cell development (Març ais et al., 2014) . Our results suggest that this pathway should also be scrutinized for its potential role in the development of adaptive NK cell responses. The signaling cascade integrates different signals and functions as a signal amplifier. Therefore, an initially relatively small difference can get larger further down in the cascade. This fit with the gradually increasing differences observed in the present study: p-CD3z/p-ZAP70 < p-SLP76 < p-Erk. Indeed, we observed a tendency for increased phosphorylation of all proximal readouts following CD2 and CD16 costimulation of adaptive NK cells. Thus, although a major difference of phosphorylation can be excluded for these early signaling events, more subtle variations might remain unseen due to a lack of sensitivity.
Given the synergy observed between NKG2C and CD2, it is plausible that CD2 can also cooperate with other DAP12-coupled receptors such as activating KIRs, although this possibility was not specifically examined here. It will be of interest to explore whether CD2 costimulation of CD16-driven responses influence the functional reprogramming of the cell during expansion in a fashion similar to that noted in the context of T cell exhaustion in autoimmunity and infection (McKinney et al., 2015) .
The expansion of adaptive NK cells in the absence of activating KIRs and NKG2C suggests that a combination of other NK receptors and or external factors contribute to elicit such responses. In this context, antibody-mediated recognition of viral antigens as a driver of adaptive NK cell responses is particularly appealing . Since CD2 is expressed at high levels on all adaptive NK cell subsets and significantly boost the response of NK cells to CD16 ligation, it is conceivable that recognition of CD58 on HCMV-infected cells play a role in shaping adaptive NK cell responses. HCMV has tropism for epithelial cells, endothelial cells, myeloid cells, and fibroblasts, all of which express CD58 (Revello and Gerna, 2010) . CMV infection also causes loss of HLA class I (Tandon and Mocarski, 2012) . Thus, CMV-infected cells fulfill all criteria for efficiently stimulating self-KIR + adaptive NK cells via CD2 and CD16. Outstanding remaining questions are to define the cellular interactions that trigger the onset of adaptive NK cell responses as well as the cellular entities that maintain stable repertoires for many years during latency. Our results point to the necessity of looking beyond NKG2C and consider the possibility that broadly expressed receptors, such as CD2, provide essential co-stimulatory signals to NK cells, corresponding to signal 2 in the generation of adaptive T cell responses (Smith-Garvin et al., 2009) .
Another major purpose of the current study was to examine whether the loss of NKG2C-driven responses had any influence on T cell-mediated immunity to HCMV. NKG2C À/À donors displayed similar frequencies of CMV-specific T cells as the NKG2C + donors, suggesting that lack of NKG2C had no major impact on the T cell response to the virus. However, we observed an accumulation of effector memory CD45RA + CD8 T cells earlier in life in HCMV + NKG2C À/À individuals, potentially indicating a stronger CD8 T cell response in the early phase of HCMV infection in the absence of NKG2C-driven adaptive NK cell immunity. This notion is supported by an extensive study of a rural population of Gambia, a country with almost universal HCMV seroprevalence; i.e., almost 100% of the population was HCMV + by 6 years of age (Goodier et al., 2014) . Although specific T cell immunity was not analyzed, immunoglobulin G (IgG) titers against HCMV were elevated in young individuals lacking the NKG2C gene. These results suggest that, despite a high level of redundancy within the NK cell compartment itself, the lack of NKG2C might also be partly compensated for by enhanced T and B cell responses, particularly during the early phases of HCMV infection. Possibly, an effective adaptive NK cell immunity helps to control the burden of HCMV infection before the emergence of efficient T and B cell immunity. Although adaptive NK cells displayed reduced degranulation responses, their enhanced ability to release cytokines in response to antibodycoated targets might help to fulfill this role and contribute to maintaining the virus silent during latency. The plasticity of adaptive NK cell responses in the absence of activating KIRs and NKG2C points to the importance of such responses within the innate immune system.
EXPERIMENTAL PROCEDURES Human Participants and Cells
This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee in Stockholm, Sweden. 2,208 random healthy blood donors were screened for NKG2C expression by flow cytometry. Donors lacking NKG2C expression were confirmed by PCR using the protocol described by Moraru et al. verifying homozygous deletion of NKG2C gene (Moraru et al., 2012a) . 60 controls expressing NKG2C and 60 donors lacking the NKG2C gene were identified and enrolled in the study. For all donors, peripheral blood mononuclear cells (PBMCs) were cryopreserved for later use. Genomic DNA was isolated using the DNeasy Blood and Tissue Kit (QIAGEN).
KIR and KIR-Ligand Typing and HCMV Serology KIR ligands were determined using the KIR HLA ligand kit (Olerup SSP; QIAGEN) for detection of the HLA-Bw4, HLA-C1, and HLA-C2 motifs. KIR genotyping was performed by using quantitative KIR automated typing (qKAT) (Jiang et al., 2012) . HCMV serology was determined using an ELISAbased assay on plasma obtained during sample preparation. Purified nuclear CMV antigen (AD 169) was used, and the cut-off level for seropositivity was an absorbance of R0.2 at a dilution of 1/100.
Flow Cytometry
A list of fluorochrome-conjugated reagents used for stainings can be found in the Supplemental Experimental Procedures. Detailed protocols of flow cytometry staining, Stochastic neighbor embedding (SNE) analysis, functional flow cytometry assays, including T and NK cell functional assays and phospho flow cytometry experiments, are provided in the Supplemental Experimental Procedures. KIR repertoire analyses were performed according to the strategy previously described (Bé ziat et al., 2014) .
DNA Methylation Analysis
DNA methylation was analyzed as previously described (Luetke-Eversloh et al., 2014) . The methylation levels of six CpG residues within the IFNG CNS1 region were analyzed via bisulfite conversion and pyrosequencing by Varionostic. Donors were selected based on the size of the three target subsets to ensure sufficient numbers of cells for methylation analysis after sorting. 
